AlphAIAlphAI — Financial news for AI agents
tradingview.com$NBIX

Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $208.59, Implies 44% Upside

Neurocrine Biosciences' average stock price target increased to $208.59 from $207.37, with a range of $150 to $253, implying 44% upside from Nov. 2 close. 31 analysts maintain a 'Buy' consensus.

Original reporting
tradingview.com
Published Nov 3, 2026, 1:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 1:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $208.59, Implies 44% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

$NBIXBullishLow
01

Why it matters

Analyst consensus upgrade signals confidence but lacks a concrete catalyst, limiting immediate trade urgency.

02

Market read

The price‑target increase may nudge the stock higher, but the news is modest and not a strong trading trigger.

03

What to watch

Potential regulatory or clinical trial risks are not reflected in the target revision.

Relevance 5/10Novelty 5/10Timing: today

Background

Neurocrine Biosciences is a biotech firm focused on treatments for endocrine and neurological disorders.

Company-level read

Ticker impact

$NBIXBullishMedium confidence
Context

Analyst consensus price target raised to $208.59, implying ~44% upside from the latest close.

Expected impact

likely upward pressure as traders price in the higher target

Evidence & confidence

Target increase reflects improved analyst outlook; no new catalyst beyond the revision, so impact is modest.

Market effects

Sector

May lift sentiment in the biotech sector as analysts show confidence in Neurocrine's pipeline.

Regional

Limited to US biotech equities; no broader regional effect.

Global

Minimal global impact; primarily relevant to investors tracking US biotech stocks.

Counterpoint

What could challenge this read

The target raise could be premature if upcoming trial data disappoints, keeping the stock volatile.

Key entities

  • company
    Neurocrine Biosciences, Inc.

    US-listed biotech company (ticker NBIX).

Read at source← All news

Related articles

$NBIXHighAI 8/10

NBIX Stock Jumps As Earnings Smash Estimates And Pipeline Expands

Neurocrine Biosciences Inc. (NBIX) stock rose 14.3% after strong Q3 earnings, with revenue of $1.12B (up from $794.9M YoY) and adjusted EPS of $3.29 (up from $2.17). The company also reported positive clinical data and expanded its pipeline, including a new Phase 2 trial for Alzheimer's treatment. Management raised FY26 revenue guidance to $2.9B–$2.925B, below consensus of $3.9B.

timothysykes.com
$NBIXHighAI 9/10

Why is Neurocrine Biosciences stock surging today?

Neurocrine Biosciences (NBIX) stock rose 15.1% after reporting Q3 adjusted earnings of $3.29 per share, beating estimates by 72%, and revenue of $1.12 billion, up 41% YoY. The company surpassed $1 billion in net product sales for the first time, driven by its top products. Analysts raised price targets, with Baird setting a $225 target. Management increased 2026 INGREZZA sales guidance to $2.9-$2.925 billion.

investing.com
$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com